Prognostic Value of G8 Geriatric Screening and Meet-URO Scores in Metastatic Renal Cell Carcinoma Patients Receiving First-Line Ipilimumab-Nivolumab Combination Immunotherapy.

Technol Cancer Res Treat · 2025 · PMC11848895 · PMID 39989333

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

of borderline significancep = 0.05actually significant

Patients with a G8 score ≤ 14 within the high Meet-URO score groups (4 and 5) exhibited the poorest outcomes in both PFS and OS although these differences were not statistically significant in PFS (p = 0.1) and of borderline significance in OS (p = 0.05) ( Supplementary Figure 1 and Supplementary Table 2 ).

also in 2,624 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.